The miR-149rs2292832 C>T was not associated with susceptibility to gastric cancer, when TT genotype was compared with the more frequent AA genotype (OR 0.98, 95% CI 0.55-1.77, p=0.96) or when we used dominant and recessive models.
Here, we performed a case-control study to investigate the role of miR-146a, miR-149, and miR-196a2 polymorphisms in the development of gastric cancer using a hospital-based case-control design.
In summary, our data provide new insights that miR-149 plays an important role in determining sensitivity of cisplatin-resistant GC cells by targeting FoxM1 and suggest that miR-149 could be a potential target for reversing drug resistance in GC.
Our results show both the homozygous miR-27a rs895819 and the miR-149rs2292832 heterozygote genotype were associated with a decreased risk of gastric cancer when compared with wild type.
We found that the risk for GC was significantly higher for the carriers of miR-149rs2292832CC (p = 0.009) and miR-196a2 rs11614913CC (p < 0.0001) genotypes, as well as for the carriers of the rs2910164/rs2292832/rs11614913 CCC and GTC haplotype (p < 0.0001 and p = 0.03, respectively).
Here we report that miR-149 is a tumor suppressor in human gastric cancer. miR-149 expression is decreased in GC cell lines and clinical specimens in comparison to normal gastric epithelial cell and tissues, respectively.
Among those that engaged in smoke inhalation, miR-149 CT/CC and miR-605 AG/GG genotype carriers had increased susceptibilities to colorectal cancer (OR = 1.90, 95% CI: 1.11-3.25) and gastric cancer (OR = 1.87, 95% CI: 1.03-3.42), respectively.